<p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）在周日发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究分析师将评级从 “买入” 下调至 “持有”。</p>
<p>其他一些券商最近也对 HAE 发表了评论。Needham &amp; Company LLC 将 Haemonetics 的目标股价从 68.00 美元上调至 78.00 美元，并在 11 月 7 日的研究报告中给予该股票 “买入” 评级。花旗集团将 Haemonetics 的目标股价从 78.00 美元下调至 64.00 美元，并在 10 月 7 日的研究报告中对该股票给予 “买入” 评级。BTIG Research 重申了 “买入” 评级，并在 11 月 21 日的研究报告中对 Haemonetics 的目标股价设定为 88.00 美元。摩根大通将 Haemonetics 的目标股价从 62.00 美元上调至 74.00 美元，并在周五的研究报告中给予该股票 “中性” 评级。最后，Raymond James Financial 重申了 “跑赢大盘” 评级，并在 11 月 14 日的研究报告中对 Haemonetics 的目标股价设定为 90.00 美元。一位股票研究分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，两位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标股价为 80.90 美元。</p>
<p><strong>查看我们关于 HAE 的最新报告</strong></p>
<h2>Haemonetics 股价下跌 1.2%</h2>
<p>Haemonetics 的股票在周五开盘价为 83.46 美元。该公司的债务与股本比率为 1.08，流动比率为 1.64，速动比率为 1.03。该股票的 50 日简单移动平均为 65.38 美元，200 日简单移动平均为 64.42 美元。该股票的市值为 39.1 亿美元，市盈率为 24.40，市盈增长比率为 1.58，贝塔值为 0.30。Haemonetics 的 1 年最低价为 47.31 美元，1 年最高价为 87.32 美元。</p>
<p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）最后一次公布季度财报是在 11 月 6 日，医疗仪器供应商报告该季度每股收益为 1.27 美元，超出分析师的共识预期 1.12 美元，超出 0.15 美元。Haemonetics 的股本回报率为 27.22%，净利润率为 12.67%。该公司该季度的收入为 3.2732 亿美元，而共识预期为 3.1161 亿美元。去年同期，该公司的每股收益为 1.12 美元。与去年同期相比，该公司的收入下降了 5.3%。Haemonetics 已将其 2026 财年的指引设定为每股收益 4.800-5.00 美元。分析师预测 Haemonetics 在当前财年将发布每股收益 4.55 美元。</p>
<h2>Haemonetics 的机构交易</h2>
<p>一些机构投资者和对冲基金最近买入和卖出了 HAE 的股票。CIBC 私人财富集团在第三季度将其在 Haemonetics 的持股比例提高了 69.3%。CIBC 私人财富集团现在拥有 1,094 股医疗仪器供应商的股票，价值 53,000 美元，此前在上个季度购买了 448 股。CIBC Bancorp USA Inc.在第三季度购买了 Haemonetics 的新股份，价值约 251,000 美元。Danske Bank A S 在第三季度收购了 Haemonetics 的新股份，价值约 665,000 美元。凯通国际资产管理有限公司在第三季度将其在 Haemonetics 的持股比例提高了 20,925.0%。凯通国际资产管理有限公司现在拥有 841 股医疗仪器供应商的股票，价值 41,000 美元，此前在该期间购买了 837 股。最后，加拿大人寿保险公司在第三季度将其在 Haemonetics 的持股比例提高了 3.7%。加拿大人寿保险公司现在拥有 35,438 股医疗仪器供应商的股票，价值 1,706,000 美元，此前在上个季度增加了 1,266 股。目前 99.67% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Haemonetics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Haemonetics 公司是一家医疗保健公司，在美国和国际上提供一系列医疗产品和解决方案。该公司提供自动化血浆采集系统、捐赠者管理软件及支持软件解决方案，包括 NexSys PCS 和 PCS2 血浆分离设备及相关一次性产品和解决方案，以及为血浆客户管理其捐赠者、运营和供应链的集成信息技术平台；以及 NexLynk DMS 捐赠者管理系统和 Donor360 应用程序。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Haemonetics</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>如何投资小型股</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Haemonetics 吗？</h2>
<p>在你考虑 Haemonetics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Haemonetics 并不在名单上。</p>
<p>虽然 Haemonetics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>华尔街禅将海蒙尼克斯（NYSE:HAE）的评级从 “买入” 下调至 “持有”。尽管如此，其他分析师的看法各异，有些分析师维持 “买入” 评级并调整目标价格。海蒙尼克斯报告了强劲的季度收益，超出预期，并对 2026 财年持乐观展望。机构投资者积极交易该股票，目前交易价格为 83.46 美元。该公司专注于医疗产品和解决方案，特别是在血浆采集系统方面</p>

<p>Haemonetics (NYSE:HAE - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Sunday.</p>
<div class="lb-trans"><p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）在周日发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究分析师将评级从 “买入” 下调至 “持有”。</p>
</div><p>A number of other brokerages also recently commented on HAE. Needham &amp; Company LLC lifted their target price on shares of Haemonetics from $68.00 to $78.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, November 7th. Citigroup reduced their price target on shares of Haemonetics from $78.00 to $64.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, October 7th. BTIG Research reiterated a &#34;buy&#34; rating and issued a $88.00 price objective on shares of Haemonetics in a research report on Friday, November 21st. JPMorgan Chase &amp; Co. raised their target price on Haemonetics from $62.00 to $74.00 and gave the stock a &#34;neutral&#34; rating in a research note on Friday. Finally, Raymond James Financial reaffirmed an &#34;outperform&#34; rating and issued a $90.00 price target on shares of Haemonetics in a research note on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $80.90.</p>
<div class="lb-trans"><p>其他一些券商最近也对 HAE 发表了评论。Needham &amp; Company LLC 将 Haemonetics 的目标股价从 68.00 美元上调至 78.00 美元，并在 11 月 7 日的研究报告中给予该股票 “买入” 评级。花旗集团将 Haemonetics 的目标股价从 78.00 美元下调至 64.00 美元，并在 10 月 7 日的研究报告中对该股票给予 “买入” 评级。BTIG Research 重申了 “买入” 评级，并在 11 月 21 日的研究报告中对 Haemonetics 的目标股价设定为 88.00 美元。摩根大通将 Haemonetics 的目标股价从 62.00 美元上调至 74.00 美元，并在周五的研究报告中给予该股票 “中性” 评级。最后，Raymond James Financial 重申了 “跑赢大盘” 评级，并在 11 月 14 日的研究报告中对 Haemonetics 的目标股价设定为 90.00 美元。一位股票研究分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，两位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标股价为 80.90 美元。</p>
</div><p><strong>View Our Latest Report on HAE</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 HAE 的最新报告</strong></p>
</div><h2>Haemonetics Trading Down 1.2%</h2>
<div class="lb-trans"><h2>Haemonetics 股价下跌 1.2%</h2>
</div><p>Shares of Haemonetics stock opened at $83.46 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. The stock's 50 day simple moving average is $65.38 and its 200-day simple moving average is $64.42. The stock has a market cap of $3.91 billion, a P/E ratio of 24.40, a P/E/G ratio of 1.58 and a beta of 0.30. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32.</p>
<div class="lb-trans"><p>Haemonetics 的股票在周五开盘价为 83.46 美元。该公司的债务与股本比率为 1.08，流动比率为 1.64，速动比率为 1.03。该股票的 50 日简单移动平均为 65.38 美元，200 日简单移动平均为 64.42 美元。该股票的市值为 39.1 亿美元，市盈率为 24.40，市盈增长比率为 1.58，贝塔值为 0.30。Haemonetics 的 1 年最低价为 47.31 美元，1 年最高价为 87.32 美元。</p>
</div><p>Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same quarter last year, the business posted $1.12 earnings per share. The firm's revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Analysts predict that Haemonetics will post 4.55 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Haemonetics（纽约证券交易所代码：HAE - 获取免费报告）最后一次公布季度财报是在 11 月 6 日，医疗仪器供应商报告该季度每股收益为 1.27 美元，超出分析师的共识预期 1.12 美元，超出 0.15 美元。Haemonetics 的股本回报率为 27.22%，净利润率为 12.67%。该公司该季度的收入为 3.2732 亿美元，而共识预期为 3.1161 亿美元。去年同期，该公司的每股收益为 1.12 美元。与去年同期相比，该公司的收入下降了 5.3%。Haemonetics 已将其 2026 财年的指引设定为每股收益 4.800-5.00 美元。分析师预测 Haemonetics 在当前财年将发布每股收益 4.55 美元。</p>
</div><h2>Institutional Trading of Haemonetics</h2>
<div class="lb-trans"><h2>Haemonetics 的机构交易</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of HAE. CIBC Private Wealth Group LLC lifted its position in shares of Haemonetics by 69.3% during the third quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier's stock worth $53,000 after purchasing an additional 448 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Haemonetics during the 3rd quarter worth approximately $251,000. Danske Bank A S acquired a new stake in Haemonetics during the 3rd quarter worth approximately $665,000. Caitong International Asset Management Co. Ltd boosted its position in Haemonetics by 20,925.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier's stock valued at $41,000 after buying an additional 837 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its stake in shares of Haemonetics by 3.7% in the third quarter. CANADA LIFE ASSURANCE Co now owns 35,438 shares of the medical instruments supplier's stock worth $1,706,000 after acquiring an additional 1,266 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近买入和卖出了 HAE 的股票。CIBC 私人财富集团在第三季度将其在 Haemonetics 的持股比例提高了 69.3%。CIBC 私人财富集团现在拥有 1,094 股医疗仪器供应商的股票，价值 53,000 美元，此前在上个季度购买了 448 股。CIBC Bancorp USA Inc.在第三季度购买了 Haemonetics 的新股份，价值约 251,000 美元。Danske Bank A S 在第三季度收购了 Haemonetics 的新股份，价值约 665,000 美元。凯通国际资产管理有限公司在第三季度将其在 Haemonetics 的持股比例提高了 20,925.0%。凯通国际资产管理有限公司现在拥有 841 股医疗仪器供应商的股票，价值 41,000 美元，此前在该期间购买了 837 股。最后，加拿大人寿保险公司在第三季度将其在 Haemonetics 的持股比例提高了 3.7%。加拿大人寿保险公司现在拥有 35,438 股医疗仪器供应商的股票，价值 1,706,000 美元，此前在上个季度增加了 1,266 股。目前 99.67% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Haemonetics Company Profile</h2>
<div class="lb-trans"><h2>Haemonetics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.</p>
<div class="lb-trans"><p>Haemonetics 公司是一家医疗保健公司，在美国和国际上提供一系列医疗产品和解决方案。该公司提供自动化血浆采集系统、捐赠者管理软件及支持软件解决方案，包括 NexSys PCS 和 PCS2 血浆分离设备及相关一次性产品和解决方案，以及为血浆客户管理其捐赠者、运营和供应链的集成信息技术平台；以及 NexLynk DMS 捐赠者管理系统和 Donor360 应用程序。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Haemonetics</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Haemonetics</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>黄金交叉股票：模式、示例和图表</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>如何投资小型股</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=HAE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Haemonetics 吗？</h2>
</div><p>Before you consider Haemonetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Haemonetics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Haemonetics 并不在名单上。</p>
</div><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Haemonetics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Heamonetics（纽约证券交易所代码：HAE）的股票评级被 Wall Street Zen 下调